Works by Inzucchi, Silvio E.

Results: 238
    1

    A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

    Published in:
    2019
    By:
    • McMurray, John J.V.;
    • DeMets, David L.;
    • Inzucchi, Silvio E.;
    • Køber, Lars;
    • Kosiborod, Mikhail N.;
    • Langkilde, Anna M.;
    • Martinez, Felipe A.;
    • Bengtsson, Olof;
    • Ponikowski, Piotr;
    • Sabatine, Marc S.;
    • Sjöstrand, Mikaela;
    • Solomon, Scott D.;
    • McMurray, John JV;
    • DeMets, David L;
    • Inzucchi, Silvio E;
    • Kosiborod, Mikhail N;
    • Langkilde, Anna Maria;
    • Martinez, Felipe A;
    • Sabatine, Marc S;
    • Solomon, Scott D
    Publication type:
    journal article
    2
    3
    4
    5
    6
    7
    8
    9

    Type 2 diabetes therapy.

    Published in:
    Postgraduate Medicine, 2002, v. 111, n. 3, p. 83
    By:
    • Mayerson, Adam B.;
    • Inzucchi, Silvio E.
    Publication type:
    Article
    10
    11
    12

    Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1932, doi. 10.1111/dom.15058
    By:
    • McGuire, Darren K.;
    • Busui, Rodica P.;
    • Deanfield, John;
    • Inzucchi, Silvio E.;
    • Mann, Johannes F. E.;
    • Marx, Nikolaus;
    • Mulvagh, Sharon L.;
    • Poulter, Neil;
    • Engelmann, Mads D. M.;
    • Hovingh, G. Kees;
    • Ripa, Maria Sejersten;
    • Gislum, Mette;
    • Brown‐Frandsen, Kirstine;
    • Buse, John B.
    Publication type:
    Article
    13

    Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 844, doi. 10.1111/dom.14933
    By:
    • Brandt‐Jacobsen, Niels H.;
    • Jürgens, Mikkel;
    • Hasbak, Philip;
    • Gæde, Peter;
    • Rossing, Peter;
    • Rasmussen, Jon J.;
    • Andersen, Camillla Fuchs;
    • Forman, Julie L.;
    • Faber, Jens;
    • Inzucchi, Silvio E.;
    • Gustafsson, Finn;
    • Schou, Morten;
    • Kistorp, Caroline
    Publication type:
    Article
    14
    15
    16
    17
    18

    Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2775, doi. 10.1111/dom.14535
    By:
    • Vaduganathan, Muthiah;
    • Inzucchi, Silvio E.;
    • Sattar, Naveed;
    • Fitchett, David H.;
    • Ofstad, Anne Pernille;
    • Brueckmann, Martina;
    • George, Jyothis T.;
    • Verma, Subodh;
    • Mattheus, Michaela;
    • Wanner, Christoph;
    • Zinman, Bernard;
    • Butler, Javed
    Publication type:
    Article
    19

    Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1426, doi. 10.1111/dom.14352
    By:
    • Nassif, Michael E.;
    • Windsor, Sheryl L.;
    • Tang, Fengming;
    • Husain, Mansoor;
    • Inzucchi, Silvio E.;
    • McGuire, Darren K.;
    • Pitt, Bertram;
    • Scirica, Benjamin M.;
    • Austin, Bethany;
    • Fong, Michael W.;
    • LaRue, Shane J.;
    • Umpierrez, Guillermo;
    • Hartupee, Justin;
    • Khariton, Yevgeniy;
    • Malik, Ali O.;
    • Ogunniyi, Modele O.;
    • Wenger, Nanette K.;
    • Kosiborod, Mikhail N.
    Publication type:
    Article
    20
    21
    22
    23

    Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1141, doi. 10.1111/dom.14015
    By:
    • Verma, Subodh;
    • Sharma, Abhinav;
    • Zinman, Bernard;
    • Ofstad, Anne Pernille;
    • Fitchett, David;
    • Brueckmann, Martina;
    • Wanner, Christoph;
    • Zwiener, Isabella;
    • George, Jyothis T.;
    • Inzucchi, Silvio E.;
    • Butler, Javed;
    • Mazer, C. David
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30

    Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.

    Published in:
    European Journal of Preventive Cardiology, 2017, v. 24, n. 15, p. 1637, doi. 10.1177/2047487317729252
    By:
    • Arnold, Suzanne V;
    • Inzucchi, Silvio E;
    • Tang, Fengming;
    • McGuire, Darren K;
    • Mehta, Sanjeev N;
    • Maddox, Thomas M;
    • Goyal, Abhinav;
    • Sperling, Laurence S;
    • Einhorn, Daniel;
    • Wong, Nathan D;
    • Khunti, Kamlesh;
    • Lam, Carolyn SP;
    • Kosiborod, Mikhail
    Publication type:
    Article
    31
    32
    33

    Letters.

    Published in:
    2002
    By:
    • Poothullil, John M.;
    • Mikhail, Nasser;
    • Inzucchi, Silvio E.;
    • Davidson, Mayer B.;
    • Holmboe, Eric S.;
    • Weeks, William B.;
    • Wallace, Amy E.;
    • Steinman, Michael A.;
    • Epstein, Ronald M.;
    • Lyman, David;
    • Mason, James;
    • Eccles, Martin;
    • Freemantle, Nick;
    • Nazareth, Irwin;
    • Haines, Andrew;
    • Drummond, Michael;
    • Nielsen, Nete Munk;
    • Rostgaard, Klaus;
    • Hjalgrim, Henrik;
    • Aaby, Peter
    Publication type:
    Letter
    34
    35
    36

    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.

    Published in:
    2022
    By:
    • Butt, Jawad H;
    • Dewan, Pooja;
    • Merkely, Béla;
    • Belohlávek, Jan;
    • Drożdż, Jarosław;
    • Kitakaze, Masafumi;
    • Inzucchi, Silvio E;
    • Kosiborod, Mikhail N;
    • Martinez, Felipe A;
    • Tereshchenko, Sergey;
    • Ponikowski, Piotr;
    • Bengtsson, Olof;
    • Lindholm, Daniel;
    • Langkilde, Anna Maria;
    • Schou, Morten;
    • Sjöstrand, Mikaela;
    • Solomon, Scott D;
    • Sabatine, Marc S;
    • Chiang, Chern-En;
    • Docherty, Kieran F
    Publication type:
    journal article
    37

    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial.

    Published in:
    Annals of Internal Medicine, 2022, v. 175, n. 6, p. 820, doi. 10.7326/M21-4776
    By:
    • Butt, Jawad H.;
    • Dewan, Pooja;
    • Merkely, Béla;
    • Belohlávek, Jan;
    • Drod, Jarosław;
    • Kitakaze, Masafumi;
    • Inzucchi, Silvio E.;
    • Kosiborod, Mikhail N.;
    • Martinez, Felipe A.;
    • Tereshchenko, Sergey;
    • Ponikowski, Piotr;
    • Bengtsson, Olof;
    • Lindholm, Daniel;
    • Langkilde, Anna Maria;
    • Schou, Morten;
    • Sjöstrand, Mikaela;
    • Solomon, Scott D.;
    • Sabatine, Marc S.;
    • Chiang, Chern-En;
    • Docherty, Kieran F.
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50